Isosorbide dinitrate inhaler and quality of life in stable angina patients

Aim. To study quality of life (QoL) dynamics in out-patient individuals with stable angina pectoris, receiving standard basal therapy plus isosorbide dinitrate (ID) in aerosol form: Isoket® aerosol. Material and methods. In total, 547 patients with effort angina were examined: 351 males (64.2%) and...

Full description

Bibliographic Details
Main Authors: A. A. Kirichenko, L. N. Panchuk
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2005-06-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/972
Description
Summary:Aim. To study quality of life (QoL) dynamics in out-patient individuals with stable angina pectoris, receiving standard basal therapy plus isosorbide dinitrate (ID) in aerosol form: Isoket® aerosol. Material and methods. In total, 547 patients with effort angina were examined: 351 males (64.2%) and 196 females (35.8%); mean age – 61.2±9.9 years; mean disease duration – 8.9±1.9 years. A questionnaire, previously used in an international study of QoL in stable angina patients treated with nitrates, IQOLAN, was used. Standard basal therapy in most participants included beta-adrenoblockers and heart rate-reducing calcium antagonists. For treatment and prevention of anginal episodes, Isoket® aerosol was administered (12.7 g of ID in 15.0 ml), instead of nitroglycerin and nitrosorbide; the effect was assessed after three months of therapy. Results. Therapy with ID aerosol was associated with substantial improvement in physical stress tolerance. QoL dynamics differed in patients with various angina functional classes (FC). Severity of anginal symptoms reduced, as well as their frequency: in females - from 79.8% to 41.4%; in males – from 80.7% to 41.1%. In subgroup with IV FC, the percentage of “substantial QoL deterioration” decreased: in females - from 100% to 60%, in males – from 94.6% to 47.8%. Conclusion. ID aerosol was highly effective for treating angina episodes in virtually all patients. Its preventive administration improved QoL, especially in patents with angina-related restriction of physical activity.
ISSN:1728-8800
2619-0125